英国正式确认无限期认可 CE 标识医疗器械，UKCA 与 CE 双路径并行 - Wiselink Group-A More Controllable, Stable, and Future-Oriented Material Direction

Home > News Center > UK Officially Confirms Indefinite Recognition of CE-Marked Medical Devices: Dual Pathways of UKCA and CE Run in Parallel

UK Officially Confirms Indefinite Recognition of CE-Marked Medical Devices: Dual Pathways of UKCA and CE Run in Parallel

Time：2026-10-23 11:33:01

On 21 October 2026 (local time), the Medicines and Healthcare products Regulatory Agency (MHRA) issued an official notice. The UK Government formally confirmed that Great Britain (England, Scotland and Wales) will indefinitely recognise medical devices and in vitro diagnostic devices (IVDs) bearing the CE mark. Medical devices with valid EU CE certification do not need repeated UK review and approval, but they still require registration with the MHRA to be legally placed on the UK market for sale.

原

文

链

接

https://www.gov.uk/government/news/government-confirms-indefinite-recognition-of-ce-marked-medical-devices

一、Core Policy Highlights

This policy outcome originates from the public consultation held from 16 Feb 2026 to 10 Apr 2026, which received more than 1,000 feedback submissions from patients, healthcare institutions, manufacturers and industry stakeholders, before the final adoption of the indefinite CE recognition scheme.

（一）CE-certified products are exempt from repeated review and approval

Medical devices and IVDs complying with EU MDR / EU IVDR with valid CE marking can be placed on the Great Britain market on a long-term basis, with no separate UK approval required. This eliminates repeated conformity assessment for manufacturers, reduces compliance burdens, and secures consistent supply of critical medical products including insulin pumps, joint replacements, diagnostic assays and surgical instruments for the NHS and patients.

Industry statistics show that over 90% of medical devices circulating on the UK market currently enter via the CE route. This policy stabilises the vast majority of existing supply chains and mitigates risks of device shortages and price hikes for NHS procurement.

（二）The domestic UKCA pathway remains in place, dual-track operation

The UKCA marking is not abolished. It remains the official route for medical device launch in the UK. Manufacturers may freely choose between two options:

Option A: Place products on the Great Britain market using existing EU CE certificates

Option B: Apply for UKCA certification proactively to secure UK-specific regulatory clearance

Meanwhile, the UK is modernising the UKCA regime through statutory updates to pre-market requirements. It also plans to introduce legislation to establish a new licensing framework for AI-enabled medical devices and software-as-a-medical-device, catering to the development of cutting-edge medical technologies.

（三）Mutual recognition ≠ lax regulation; post-market compliance obligations remain stringent

This is the most commonly misunderstood clause of the policy. While CE-marked products gain market access, all MHRA post-market obligations remain fully applicable. The MHRA will continue to supervise all medical devices sold in the UK, carry out post-market monitoring through the Yellow Card adverse incident reporting scheme, strengthen post-market surveillance and reporting duties, and share safety information with international regulators. The MHRA retains authority to implement regulatory actions to protect patient safety once hazards are identified.

The MHRA reserves powers to conduct market audits, initiate recalls and restrict sales. For manufacturers, although pre-market entry requirements are simplified, ongoing post-market compliance becomes a permanent priority. Missing post-market documentation or failing reporting procedures will still result in penalties and product withdrawal.

（四）Clarified geographic scope: Great Britain ≠ the whole UK

The policy applies exclusively to England, Scotland and Wales. Northern Ireland follows separate rules and retains its original EU-aligned access arrangements. Companies selling across multiple territories need separate compliance planning.

（五）Alignment with the UK Life Sciences Strategy

This measure forms a key component of MHRA’s 2030 Strategy: expanding mutual recognition with trusted regulators, lowering regulatory barriers, enhancing supply chain resilience, accelerating patient access to innovative medical devices, matching the UK’s life sciences industrial roadmap and Ten-Year Health Plan, and building a more attractive medtech ecosystem.

二、In-depth Industry Analysis

（一）Underlying policy logic: balancing supply chain security and domestic regulatory autonomy

Post-Brexit, the UK originally planned to phase out CE recognition and fully transition to UKCA. Successive extensions exposed implementation bottlenecks: limited capacity and resources among UK Approved Bodies meant a mandatory switch to UKCA would trigger a backlog of uncertified devices and severely disrupt NHS procurement and clinical supply.

Indefinite mutual recognition is fundamentally a pragmatic compromise. It leverages the mature EU MDR/IVDR assessment framework to guarantee supply while preserving UKCA as a reserve instrument to retain the UK’s autonomy to adjust regulatory standards. The decision reassures healthcare providers and patients, and delivers long-term certainty to global manufacturers.

（二）Uneven benefits for different types of manufacturers

Manufacturers focused primarily on the EU market, with UK as a secondary market: This policy brings the greatest benefit. Additional UKCA investment is unnecessary; a single CE certificate covers both EU and Great Britain markets, greatly amortising compliance costs without dedicated registration timelines for a secondary market.
Manufacturers deeply rooted in the UK market and bidding for NHS tenders: A prudent evaluation is recommended. Although CE marking is acceptable, major future tenders may show preference for suppliers holding UKCA certification. Brands with long-term UK market ambitions may schedule UKCA certification as a regulatory asset to hedge against potential future policy shifts.
Manufacturers at the new product planning stage: Great Britain can be treated as an add-on market under the CE pathway. Prioritise EU MDR/IVDR clearance to simultaneously cover the EU and Great Britain. However, the compliance system must be built with the UK Responsible Person, adverse incident reporting and post-market monitoring workflows in advance; do not focus solely on certification and neglect back-end compliance systems.
IVD manufacturers: Eligible under this policy. Given the lengthy review cycles and limited certificate availability under IVDR, this stable mutual recognition landscape is particularly valuable for in vitro diagnostic exporters.

（三）Long-term risks must not be overlooked amid favourable outcomes

Indefinite recognition does not equal permanent, irreversible rules. The UK explicitly reserves the right to revise legislation; the change is the removal of fixed expiry deadlines. Compared with the annual renewal anxiety of previous years, the framework is now long-term stable, but continuous tracking of MHRA legislative updates remains mandatory. Another latent risk is regulatory divergence between the EU and UK. Future revisions to EU MDR and standalone updates to UKCA rules will gradually widen gaps in technical requirements and review priorities. Manufacturers relying solely on CE marking may face mismatched compliance requirements for certain product categories down the line.

（四）Impacts on the landscape of Chinese medical device exports

Repeated policy swings in the UK previously discouraged many Chinese manufacturers from investing in customer development. With regulatory certainty now confirmed, Great Britain becomes a more cost-effective export destination.

For Chinese foreign trade and compliance service providers, market demand will shift: UKCA consultation demand will cool in the short run, while demand for post-market compliance system setup, UK Responsible Person services, Yellow Card reporting and PSUR drafting will rise. Certificate acquisition alone will no longer be the core requirement; sustained post-market compliance operation will become a lasting priority.

三、Practical Recommendations for Medical Device Manufacturers

Audit the validity of existing CE certificates, confirming certificates, technical documentation and Notified Bodies remain compliant. Expired CE certificates cannot support continued market access to Great Britain.
Complete the setup of the UK Responsible Person and post-market surveillance workflow as soon as possible, and build adverse event collection and Yellow Card reporting mechanisms – this remains the weakest link for most Chinese manufacturers.
Select your compliance route based on commercial strategy: choose the CE pathway for low-volume, lightweight UK market entry; schedule UKCA certification in batches if long-term NHS tendering and deep UK market penetration are planned.
Establish a regulatory tracking mechanism, and keep track of UKCA modernisation reforms, AI medical device rules and Northern Ireland access changes to avoid cross-territory compliance confusion.
Confirm qualification requirements with procurement teams before tendering. Some NHS programmes have internal preferences, so never assume CE marking automatically satisfies tender criteria.

四、Conclusion

Overall, this policy release lifts the multi-year countdown pressure for overseas manufacturers, yet it does not mean compliance can be neglected. Under the dual-track framework, opportunities and latent risks coexist long-term. Instead of waiting passively, enterprises should sort out their UK post-market compliance workflows according to their market layout, and secure initiative for sustainable operations amid this new certainty.If you need further support, feel free to contact Wiselink.

Previous：KGMP: On-site Inspection or Document Review? CMEF Open Class Exclusive Insights Next：FDA PCCP In-Depth Interpretation: The Fast Track for Iterative Updates of AI Medical Devices

Fill Form

Whether you need more information or wish to cooperate with us, we will guide you through every step of the regulatory process. Subscribe to our newsletter for the latest global regulatory updates.